Synlogic, Inc.

As of March 6, 2025, Synlogic, Inc. is considered overvalued and has been downgraded to "does not qualify" due to unfavorable financial metrics and poor stock performance compared to its peers and the S&P 500.

As of May 1, 2025, Synlogic, Inc. exhibits a mildly bearish trend due to bearish daily moving averages and Bollinger Bands, despite some mildly bullish signals from the MACD and KST, resulting in a mixed overall sentiment.

As of March 2022, the management team of Synlogic, Inc. includes Dr. Peter Barrett (Independent Chairman), Dr. Aoife Brennan (CEO), and several independent directors: Mr. Michael Heffernan, Dr. Michael Burgess, Dr. Patricia Hurter, Mr. Chau Khuong, and Mr. Nick Leschly. They oversee the company's strategic direction and operations.

Synlogic, Inc. develops Synthetic Biotic medicines for rare genetic diseases and operates in the micro-cap Pharmaceuticals & Biotechnology sector, with a market cap of $14.50 million. The company is currently loss-making, with no dividend yield and negative return on equity.

As of Jun 18, Synlogic, Inc. has a market capitalization of 14.50 million, categorizing it as a Micro Cap company, with shareholder's funds of 12.75 million and total assets of 19.83 million as of December 2024.